購物車 
-
一甲基澳瑞他汀 F
- names：
Monomethyl Auristatin F
- CAS號：
745017-94-1
MDL Number： MFCD25976742 - MF(分子式)： C39H65N5O8 MW(分子量)： 731.96
- EINECS:Not available Reaxys Number:Not available
- Pubchem ID:10395173 Brand:BIOFOUNT
一甲基澳瑞他汀 F(745017-94-1,Monomethyl Auristatin F,MMAF)是一種有效的微管蛋白聚合抑制劑，一甲基澳瑞他汀 F具有腫瘤抗性。MMAF (Monomethylauristatin F) 廣泛用作抗體偶聯(lián)藥物 (ADCs) 的細胞毒性成分，如 Vorsetuzumab mafodotin 和 SGN-CD19A。
| 貨品編碼 | 規(guī)格 | 純度 | 價格 (￥) | 現(xiàn)價(￥) | 特價(￥) | 庫存描述 | 數(shù)量 | 總計 (￥) |
|---|---|---|---|---|---|---|---|---|
| HCC336667-5mg | 5mg | 97% | ￥ 2593.50 | ￥ 2593.50 | 4-7周 | ￥ 0.00 |
| 中文別名 | 一甲基澳瑞他汀 F(745017-94-1,Monomethyl Auristatin F,MMAF),一甲基瑞奧西汀F,甲基澳瑞他汀F |
| 英文別名 | Monomethyl Auristatin F,745017-94-1,MMAF |
| CAS號 | 745017-94-1 |
| Inchi | InChI=1S/C39H65N5O8/c1-12-25(6)34(43(9)38(48)33(24(4)5)42-37(47)32(40-8)23(2)3)30(51-10)22-31(45)44-20-16-19-29(44)35(52-11)26(7)36(46)41-28(39(49)50)21-27-17-14-13-15-18-27/h13-15,17-18,23-26,28-30,32-35,40H,12,16,19-22H2,1-11H3,(H,41,46)(H,42,47)(H,49,50)/t25-,26+,28-,29-,30+,32-,33-,34-,35+/m0/s1 |
| InchiKey | MFRNYXJJRJQHNW-DEMKXPNLSA-N |
| 分子式 Formula | C39H65N5O8 |
| 分子量 Molecular Weight | 731.96 |
| 溶解度Solubility | DMF (Slightly), DMSO (Slightly), Methanol (Slightly), Water (Slightly) |
| 性狀 | 白色固體粉末 |
| 儲藏條件 Storage conditions | 干燥，避光，短期（幾天至幾周）處于0-4°C，長期（幾個月至幾年）處于-20°C。 |
一甲基澳瑞他汀 F(745017-94-1,Monomethyl Auristatin F,MMAF) 實驗注意事項：
1.實驗前需戴好防護眼鏡，穿戴防護服和口罩，佩戴手套，避免與皮膚接觸。
2.實驗過程中如遇到有毒或者刺激性物質(zhì)及有害物質(zhì)產(chǎn)生，必要時實驗操作需要手套箱內(nèi)完成以免對實驗人員造成傷害
3.實驗后產(chǎn)生的廢棄物需分類存儲，并交于專業(yè)生物廢氣物處理公司處理，以免造成環(huán)境污染
Monomethyl Auristatin F(745017-94-1,MMAF) Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
Tag:一甲基澳瑞他汀 F(745017-94-1,Monomethyl Auristatin F,MMAF),一甲基澳瑞他汀 F試劑,一甲基澳瑞他汀 F抑制劑,一甲基澳瑞他汀 F的作用,一甲基澳瑞他汀 F的合成,一甲基澳瑞他汀 F的純度,一甲基澳瑞他汀 F的生產(chǎn),一甲基澳瑞他汀 F的MSDS
| 產(chǎn)品說明 | 一甲基澳瑞他汀 F(745017-94-1,Monomethyl Auristatin F,MMAF)是一種有效的微管蛋白聚合抑制劑，一甲基澳瑞他汀 F具有腫瘤抗性。 |
| Introduction | Monomethyl Auristatin F (745017-94-1, 一甲基澳瑞他汀 F, MMAF) is a potent inhibitor of tubulin polymerization. Monomethyl Auristatin F has tumor resistance. |
| Application1 | Monomethyl Auristatin F (745017-94-1, 一甲基澳瑞他汀 F, MMAF) can be used as a reference substance for drug impurities and reagents，only for research. |
| Application2 | |
| Application3 |
Monomethyl auristatin F (MMAF) is a synthetic antineoplastic agent. It is part of some experimental anti-cancer antibody-drug conjugates such as vorsetuzumab mafodotin and SGN-CD19A. In International Nonproprietary Names for MMAF-antibody-conjugates, the name mafodotin refers to MMAF plus its attachment structure to the antibody.
| 警示圖 | |
| 危險性 | warning |
| 危險性警示 | Not available |
| 安全聲明 | H303+H313+H333 |
| 安全防護 | P264+P280+P305+P351+P338+P337+P313 |
| 備注 | 實驗過程中防止吸入、食入，做好安全防護 |
| CytotoxicPayloadsforAntibody–DrugConjugates,CHAPTER4AuristatinPayloadsforAntibody–DrugConjugates(ADCs).SvetlanaO.Doronina,PeterD.Senter,2019 |
| Pages73-99CytotoxicPayloadsforAntibody–DrugConjugates,SubjectIndex,2019 |
| Pages472-480CytotoxicPayloadsforAntibody–DrugConjugates,Contents,2019 |
| PagesP011-P021CytotoxicPayloadsforAntibody–DrugConjugates,CHAPTER6Colchicine-,Vinblastine-,Taxol-andEribulin-basedPayloadsforAntibody–DrugConjugates(ADCs).ArpitaVelani,SyafiqKay,EarlF.Albone,DavidE.Thurston,2019 |
| Pages117-136Biotherapeutics:RecentDevelopmentsusingChemicalandMolecularBiology,CHAPTER6RecentAdvancesinAntibody–DrugConjugates.EdmundI.Graziani,L.NathanTumey,2013 |
1.Improved efficacy of alphavbeta3-targeted albumin conjugates by conjugation of a novel auristatin derivative.
Temming K;Meyer DL;Zabinski R;Senter PD;Poelstra K;Molema G;Kok RJ Mol Pharm. 2007 Sep-Oct;4(5):686-94. Epub 2007 Aug 8.
Cellular handling of drug delivery preparations en route to the lysosomal compartment has been extensively studied, but little is known about cellular handling of drugs subsequent to their release from the delivery system. We studied a series of closely related drug targeting conjugates, consisting of albumins equipped with alpha vbeta 3-selective RGD-peptide homing ligands, PEG stealth domains, and either the antitubulin agent monomethyl auristatin E (MMAE) or a new F-variant (MMAF). Since MMAF has a C-terminal charge, this compound is potentially less prone to passive redistribution after its release from the carrier. We demonstrate that RGD-peptide-equipped albumin conjugates with MMAF were indeed more potent than MMAE conjugates, in killing both alpha vbeta 3-positive tumor cells and proliferating endothelial cells. Efficacy increased more in tumor cells than in endothelial cells, suggesting different drug redistribution behavior for the two cell types. Binding affinity and uptake of the conjugate and the cellular handling of released drug contributed to the final efficacy of drug-carrier conjugates, highlighting the importance of all aspects to be carefully considered in the design of targeted drug delivery preparations.
Temming K;Meyer DL;Zabinski R;Senter PD;Poelstra K;Molema G;Kok RJ Mol Pharm. 2007 Sep-Oct;4(5):686-94. Epub 2007 Aug 8.
Cellular handling of drug delivery preparations en route to the lysosomal compartment has been extensively studied, but little is known about cellular handling of drugs subsequent to their release from the delivery system. We studied a series of closely related drug targeting conjugates, consisting of albumins equipped with alpha vbeta 3-selective RGD-peptide homing ligands, PEG stealth domains, and either the antitubulin agent monomethyl auristatin E (MMAE) or a new F-variant (MMAF). Since MMAF has a C-terminal charge, this compound is potentially less prone to passive redistribution after its release from the carrier. We demonstrate that RGD-peptide-equipped albumin conjugates with MMAF were indeed more potent than MMAE conjugates, in killing both alpha vbeta 3-positive tumor cells and proliferating endothelial cells. Efficacy increased more in tumor cells than in endothelial cells, suggesting different drug redistribution behavior for the two cell types. Binding affinity and uptake of the conjugate and the cellular handling of released drug contributed to the final efficacy of drug-carrier conjugates, highlighting the importance of all aspects to be carefully considered in the design of targeted drug delivery preparations.
對不起，暫無產(chǎn)品評價！
MSDS
SDS 1.0 中文
展開
SDS 1.0 英文
展開
- 相關(guān)產(chǎn)品
-
< >
- 推薦產(chǎn)品
-
< >
- 最新產(chǎn)品
-
< >
新聞
怎么做細胞爬片免疫組化染色實驗
細胞爬片免疫組化染色，是通過細胞爬片是讓玻片浸在細胞培養(yǎng)基內(nèi)，細胞在玻片上生長，主要用于組織學，免疫組織化學...
2020/7/20 22:04:33
提取病毒RNA的實驗方法
提取病毒RNA方法分別有：異硫氰酸胍的提取病毒RNA方法、TRIzol LS提取法、Trizol法提取法等等...
2020/7/22 20:29:26
細胞培養(yǎng)耗材技術(shù)領(lǐng)先性
細胞培養(yǎng)板行業(yè)面臨的核心痛點是：常規(guī)TC處理后表面親水角隨時間衰減，影響長期培養(yǎng)穩(wěn)定性，BIOFOUNT高分...
2026/4/28 15:12:51
板.jpg)
細胞培養(yǎng)耗材關(guān)鍵性能
細胞培養(yǎng)板的水接觸角作為表面潤濕性的核心指標，直接影響細胞貼壁、增殖、分化及功能表達，其中40°（低接觸角/...
2026/4/28 14:52:44
chelex 100樹脂國產(chǎn)替代之路-BIOFOUNT范德生物
Chelex 100螯合離子交換樹脂對銅、鐵和其他重金屬?的偏好顯著高于對鈉、鉀等一價陽離子的偏好。它對二價...
2025/11/4 14:22:46
9月開學季——助研新學期 范德送好禮
2025/8/28 15:30:55
Waxfilm 實驗室封口膜：技術(shù)與國際市場的雙重突破
在實驗室耗材領(lǐng)域，封口膜是保障實驗準確性與穩(wěn)定性的關(guān)鍵產(chǎn)品之一。近年來，Waxfilm?實驗室封口膜憑借其卓...
2025/5/13 13:03:40
Waxfilm實驗室封口膜的5大突破
Waxfilm實驗室封口膜作為生物功能膜領(lǐng)域的國產(chǎn)技術(shù)突破和品牌突破，是生物領(lǐng)域中國技術(shù)發(fā)展的縮影。
2025/5/6 17:02:07
各種微流控芯片鍵合方法的優(yōu)缺點
微流控芯片鍵合：目前主要有激光焊接、熱壓鍵合、膠鍵合、超音波焊接，每種方法都有各自的優(yōu)缺點。本文主要介紹聚酯...
2023/7/28 10:43:09
新一代微流控鍵合解決方案
微流控鍵合解決方案：微流控芯片制造的一個重要環(huán)節(jié)，也是最容易被忽視的--芯片鍵合。其中一個重要因素是：微流控...
2023/7/27 12:44:28
